The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease was written by Brakedal, Brage;Dolle, Christian;Riemer, Frank;Ma, Yilong;Nido, Gonzalo S.;Skeie, Geir Olve;Craven, Alexander R.;Schwarzlmuller, Thomas;Brekke, Njaal;Diab, Joseph;Sverkeli, Lars;Skjeie, Vivian;Varhaug, Kristin;Tysnes, Ole-Bjoern;Peng, Shichun;Haugarvoll, Kristoffer;Ziegler, Mathias;Gruner, Renate;Eidelberg, David;Tzoulis, Charalampos. And the article was included in Cell Metabolism in 2022.Product Details of 1094-61-7 The following contents are mentioned in the article:
We conducted a double-blinded phase I clin. trial to establish whether NAD (NAD) replenishment therapy, via oral intake of nicotinamide riboside (NR), is safe, augments cerebral NAD levels, and impacts cerebral metabolism in Parkinson’s disease (PD). Thirty newly diagnosed, treatment-naive patients received 1,000 mg NR or placebo for 30 days. NR treatment was well tolerated and led to a significant, but variable, increase in cerebral NAD levels-measured by 31phosphorous magnetic resonance spectroscopy-and related metabolites in the cerebrospinal fluid. NR recipients showing increased brain NAD levels exhibited altered cerebral metabolism, measured by 18fluoro-deoxyglucose positron emission tomog., and this was associated with mild clin. improvement. NR augmented the NAD metabolome and induced transcriptional upregulation of processes related to mitochondrial, lysosomal, and proteasomal function in blood cells and/or skeletal muscle. Furthermore, NR decreased the levels of inflammatory cytokines in serum and cerebrospinal fluid. Our findings nominate NR as a potential neuroprotective therapy for PD, warranting further investigation in larger trials. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate (cas: 1094-61-7Product Details of 1094-61-7).
((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate (cas: 1094-61-7) belongs to amides. Amides can be viewed as a derivative of a carboxylic acid RC(=O)OH with the hydroxyl group –OH replaced by an amine group −NR′R″; or, equivalently, an acyl (alkanoyl) group RC(=O)− joined to an amine group. As a result of interactions such as these, the water solubility of amides is greater than that of corresponding hydrocarbons. These hydrogen bonds are also have an important role in the secondary structure of proteins.Product Details of 1094-61-7
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics